Ontuxizumab (MORAb-004) is a humanised monoclonal antibody targeting endosialin, and has shown preliminary anti-tumour activity in a Phase I trial in treatment-refractory solid tumours, including sarcoma patients (Diaz et al, 2015). The gene discussed is CD248; the disease is sarcoma.